Sort   by:  
 Page size 
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
GenomicsGenome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors (ChIP-Seq)
Inactivating mutations in the MEN1 gene predisposing to the multiple endocrine neoplasia type 1 (MEN1) syndrome can also cause sporadic pancreatic endocrine tumors. MEN1 encodes menin, a subunit of MLL1/MLL2-containing histone methyltransferase complexes that trimethylate histone H3 at lysine 4 (H3K...
ORGANISM(S): Mus musculus 
2012-06-01 | E-GEOD-37774 | biostudies-arrayexpress
MetabolomicsInvestigating exposures and health impacts of endocrine disrupting chemicals among inner-city children.
Not available
ORGANISM(S): Homo sapiens 
ST001383 | MetabolomicsWorkbench
TranscriptomicsTranscription profiling of cells from four developmental stages of human endocrine pancreas to define genetic pathways that regulate endocrine pancreatic development
To define genetic pathways that regulate development of the endocrine pancreas, we generated transcriptional profiles of enriched cells isolated from four biologically significant stages of endocrine pancreas development: endoderm before pancreas specification, early pancreatic progenitor cells, end...
ORGANISM(S): Mus musculus 
2006-06-30 | E-CBIL-14 | biostudies-arrayexpress
GenomicsGenome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
The estrogen receptor alpha (ERa) drives the growth of two-thirds of all breast cancers. Endocrine therapy impinges on estrogen-induced ERa activation to block tumor growth. However, half of ERa-positive breast cancers are tolerant or acquire endocrine therapy resistance. Here we demonstrate that br...
ORGANISM(S): Homo sapiens 
2013-05-01 | E-GEOD-37323 | biostudies-arrayexpress
MetabolomicsMetabolite expression in liver after early life exposure to an endocrine disruptor at 240 days postnatal (part-I)
Not available
ORGANISM(S): Rattus norvegicus 
ST001309 | MetabolomicsWorkbench
MetabolomicsLipid expression in serum after early lifer exposure to an endocrine disruptor at 70 days postnatal (part-III)
Not available
ORGANISM(S): Rattus norvegicus 
ST001312 | MetabolomicsWorkbench
MetabolomicsLipid expression in liver after early lifer exposure to an endocrine disruptor at 70 days postnatal (part-II)
Not available
ORGANISM(S): Rattus norvegicus 
ST001311 | MetabolomicsWorkbench
MetabolomicsMetabolic adaptations in an endocrine-related breast cancer mouse model unveil potential markers of tumor response to hormonal therapy
Not available
ORGANISM(S): Mus musculus 
ST001984 | MetabolomicsWorkbench
TranscriptomicsFoxA1 is a critical determinant of Estrogen Receptor function and endocrine response
This SuperSeries is composed of the following subset Series: GSE25314: FoxA1 is a critical determinant of Estrogen Receptor function and endocrine response (part I) GSE25315: FoxA1 is a critical determinant of Estrogen Receptor function and endocrine response (part II) Refer to individual Series
ORGANISM(S): Homo sapiens 
2010-11-17 | E-GEOD-25316 | biostudies-arrayexpress
Sort   by:  
 Page size